Comparing 2 hypotheses side-by-side
FDA-approved P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) cross the BBB to variable extents and inhibit P2RY12 in cerebral VSMCs, restoring autophagy flux, reducing foam cell formation, and improving Aβ clearance. This represents the most operationally feasible hypothesis for immediate testing. However, these drugs are primarily antiplatelet agents; any neurovascular benefit could arise from reduced platelet activation, microthrombi, inflammation, or systemic cardiovascular effects rath
**Molecular Mechanism and Rationale** The P2Y12 receptor, encoded by the P2RY12 gene, represents a critical component of microglial surveillance and activation machinery in the central nervous system. This Gi/Go-coupled purinergic receptor responds to extracellular adenosine diphosphate (ADP) and adenosine triphosphate (ATP) released from neurons and other glial cells. Under physiological conditions, P2Y12 receptors maintain microglial processes in a dynamic, highly motile state that enables co
| Dimension | Pharmacological P2RY12 inhibit | Purinergic P2Y12 Inverse Agoni |
|---|---|---|
| Mechanistic | 0.480 | 0.750 |
| Evidence | 0.580 | 0.650 |
| Novelty | 0.400 | 0.800 |
| Feasibility | 0.850 | 0.700 |
| Impact | 0.720 | 0.720 |
| Druggability | 0.880 | 0.850 |
| Safety | 0.300 | 0.550 |
| Competition | 0.650 | 0.750 |
| Data | 0.550 | 0.600 |
| Reproducible | 0.620 | 0.580 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.62
# Therapeutic/Mechanistic Hypotheses: P2RY12-Mediated VSMC Dysfunction in Cerebrovascular Neurodegeneration --- ## Hypothesis 1: P2RY12-Driven Autophagy Impairment in Cerebral VSMCs Mediates Blood-B...
Below I’m using the source paper’s core result as the anchor: P2RY12 activation in VSMCs promoted foam-cell formation by suppressing autophagy through PI3K-AKT-MTOR in an atherosclerosis model, not sp...
**Bottom Line** The most feasible surviving program is not “repurpose ticagrelor for Alzheimer’s.” It is a staged target-validation program testing whether **P2RY12 is functionally present in cerebra...
```json { "ranked_hypotheses": [ { "title": "P2RY12-mediated autophagy inhibition in cerebral VSMCs impairs CAA clearance", "description": "Vascular smooth muscle cells clear Aβ from...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["Extracellular
ADP/ATP Release"] --> B["P2Y12 Receptor
Activation"]
B --> C["Gi/Go Protein
Coupling"]
C --> D["Adenylyl Cyclase
Inhibition"]
D --> E["Decreased cAMP
Levels"]
E --> F["PI3K/Akt Pathway
Activation"]
F --> G["Rho GTPase
Activation
(Rac1/CDC42)"]
G --> H["Actin Cytoskeletal
Reorganization"]
H --> I["Microglial Process
Extension"]
I --> J["Enhanced Synaptic
Surveillance"]
J --> K["Excessive Synaptic
Pruning"]
K --> L["Neuronal Network
Dysfunction"]
L --> M["Neurodegeneration
Progression"]
N["P2Y12 Inverse
Agonist Therapy"] --> B
N -->|"Blocks"| C
O["Therapeutic
Outcome"] --> L
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,C,D,E normal
class N therapeutic
class I,J,K,L,M pathology
class O outcome
class F,G,H molecular